Announcements
27 June 2024
Antibodies | Highly Viewed Papers in 2022–2023 in Section the “Antibody-Based Diagnostics”
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
As all of the articles published in our journal are in an open access format, you have free and unlimited access to the full texts. We welcome you to read our most highly viewed papers published in 2022 and 2023 listed below.
1. “IgG Avidity Test as a Tool for Discrimination between Recent and Distant Toxoplasma gondii Infection—Current Status of Studies”
by Lucyna Holec-Gąsior and Karolina Sołowińska
Antibodies 2022, 11(3), 52; https://doi.org/10.3390/antib11030052
Available online: https://www.mdpi.com/2073-4468/11/3/52
2. “New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond”
by Marino Paroli, Chiara Gioia and Daniele Accapezzato
Antibodies 2023, 12(1), 25; https://doi.org/10.3390/antib12010025
Available online: https://www.mdpi.com/2073-4468/12/1/25
3. “IgA Nephropathy: Current Treatment and New Insights”
by Dimitra Petrou, Petros Kalogeropoulos, George Liapis and Sophia Lionaki
Antibodies 2023, 12(2), 40; https://doi.org/10.3390/antib12020040
Available online: https://www.mdpi.com/2073-4468/12/2/40
4. “When Autoantibodies Are Missing: The Challenge of Seronegative Rheumatoid Arthritis”
by Marino Paroli and Maria Isabella Sirinian
Antibodies 2023, 12(4), 69; https://doi.org/10.3390/antib12040069
Available online: https://www.mdpi.com/2073-4468/12/4/69
5. “From Cereal Grains to Immunochemistry—What Role Have Antibodies Played in the History of the Home Pregnancy Test”
by Kinga Lis
Antibodies 2023, 12(3), 56; https://doi.org/10.3390/antib12030056
Available online: https://www.mdpi.com/2073-4468/12/3/56
6. “Antibodies for β2-Microglobulin and the Heavy Chains of HLA-E, HLA-F, and HLA-G Reflect the HLA-Variants on Activated Immune Cells and Phases of Disease Progression in Rheumatoid Arthritis Patients under Treatment”
by Mepur H. Ravindranath, Narendranath M. Ravindranath, Carly J. Amato-Menker, Fatiha El Hilali, Senthamil R. Selvan, Edward J. Filippone and Luis Eduardo Morales-Buenrostro
Antibodies 2023, 12(2), 26; https://doi.org/10.3390/antib12020026
Available online: https://www.mdpi.com/2073-4468/12/2/26